A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog

Area of Science:

• Biochemistry
• Endocrinology
• Protein Engineering

Background:

• Fibroblast Growth Factor 21 (FGF21) is a promising therapeutic hormone for metabolic diseases.
• Current FGF21 therapies face limitations due to poor bio-stability, aggregation, and degradation.
• Overcoming these limitations is crucial for developing effective FGF21-based treatments.

Purpose of the Study:

• To engineer recombinant human FGF21 variants with improved therapeutic properties.
• To develop a generalized solid-phase PEGylation strategy for enhancing protein therapeutic half-life.
• To demonstrate the efficacy of engineered FGF21 as a prototype for improved protein therapeutics.

Main Methods:

• Site-directed mutagenesis was used to introduce cysteine residues into FGF21.
• A solid-phase nickel affinity PEGylation strategy was employed for site-selective conjugation.
• Engineered, surface-exposed cysteines served as a platform for PEG conjugation.

Main Results:

• Engineered PEGylated FGF21 conjugates maintained biological functions.
• The half-life of the engineered FGF21 conjugates increased by over 211.3 minutes.
• The study successfully demonstrated the biological activity of the FGF21 analog.

Conclusions:

• The developed FGF21 variants exhibit enhanced bio-stability and extended serum half-life.
• The generalized solid-phase PEGylation approach is effective for improving protein therapeutics.
• This strategy offers a promising pathway for developing novel treatments for metabolic diseases.